Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors | Zendy

Karin Leander | Zendy; Anders Mälarstig | Zendy; Ferdinand M. van’t Hooft | Zendy; Craig Hyde | Zendy; Mai-Lis Hellénius | Zendy; Jason S. Troutt | Zendy; Robert J. Konrad | Zendy; John Öhrvik | Zendy; Anders Hamsten | Zendy; Ulf dé Fairé | Zendy

Open Access

Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors

Author(s) -

Karin Leander,

Anders Mälarstig,

Ferdinand M. van’t Hooft,

Craig Hyde,

Mai-Lis Hellénius,

Jason S. Troutt,

Robert J. Konrad,

John Öhrvik,

Anders Hamsten,

Ulf dé Fairé

Publication year - 2016

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.115.018531

Subject(s) - medicine , hazard ratio , pcsk9 , confidence interval , kexin , population , proportional hazards model , type 2 diabetes , quartile , cardiology , diabetes mellitus , endocrinology , cholesterol , lipoprotein , ldl receptor , environmental health

The secreted protein proprotein convertase subtilisin/kexin type 9 (PCSK9) is a promising new target for lowering plasma low-density lipoprotein cholesterol and preventing cardiovascular disease (CVD). The relationship between circulating PCSK9 and incident CVD in the general population is unknown. We investigated whether serum PCSK9 concentration is associated with incident CVD in a prospective cohort study of 4232 men and women 60 years of age at the time of recruitment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research